Biogen spells out remarkable efficacy data in Alzheimer's for aducanumab, but safety threat persists
Shares of Biogen jumped Thursday afternoon after an updated assessment of the remarkably positive data they’ve been collecting from the PRIME study of their Alzheimer’s drug hopeful aducanumab was leaked among investors and then quickly spread online.
Aside from the kerfuffle over how the data first began to surface, a close look at the full set of results revealed a surprisingly positive readout that will help ignite renewed enthusiasm for Biogen’s prospects in what is perhaps the toughest field in R&D — though a big safety issue remains a key concern.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters